Research programme: opioid analgesics - Relmada Therapeutics

Drug Profile

Research programme: opioid analgesics - Relmada Therapeutics

Alternative Names: REL-1041

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Relmada Therapeutics
  • Class Opioid analgesics
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (PO, Controlled release)
  • 31 Aug 2012 Preclinical trials in Pain in USA (PO)
  • 31 Aug 2012 Pharmacokinetics data from preclinical trials in Pain presented at the 14th World Congress on Pain (WCP-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top